UPM-Kymmene Corporation: Managers’ Transactions (Reynaudo)

UPM-Kymmene Corporation                Managers’ Transactions                26 February 2024 at 16:00 EET

UPM-Kymmene Corporation: Managers’ Transactions (Reynaudo) 

UPM-Kymmene Corporation has on 26 February 2024 received the following notification:
____________________________________________

Person subject to the notification requirement
Name: Reynaudo, Massimo
Position: Chief Executive Officer
Issuer: UPM-Kymmene Corporation
LEI: 213800EC6PW5VU4J9U64
Notification type: INITIAL NOTIFICATION
____________________________________________

Transaction date: 2024-02-26
Venue not applicable
Instrument type: SHARE
ISIN: FI0009005987
Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE

Transaction details
(1): Volume: 2,954 Unit price: 0.00 EUR

Aggregated transactions
(1): Volume: 2,954 Volume weighted average price: 0.00 EUR
____________________________________________

UPM-Kymmene Corporation
Pirkko Harrela
Executive Vice President, Stakeholder Relations

UPM, Media Relations
Mon-Fri 9:00–16:00 EET
tel. +358 40 588 3284
[email protected]

UPM
We deliver renewable and responsible solutions and innovate for a future beyond fossils across six business areas: UPM Fibres, UPM Energy, UPM Raflatac, UPM Specialty Papers, UPM Communication Papers and UPM Plywood. As the industry leader in responsibility, we are committed to the UN Business Ambition for 1.5°C and the science-based targets to mitigate climate change. We employ 16,600 people worldwide and our annual sales are approximately EUR 10.5 billion. Our shares are listed on Nasdaq Helsinki Ltd. UPM Biofore – Beyond fossils. www.upm.com

Follow UPM on X | LinkedIn | Facebook | YouTube | Instagram | #UPM #biofore #beyondfossils

You May Also Be Interested In

• TetherMax Names South Korean Actor Yoon Shi-yoon as Brand Ambassador to Expand Presence Across Asia
• THE WINTRUST MAGNIFICENT MILE LIGHTS FESTIVAL® CELEBRATES ITS MILESTONE 35TH ANNIVERSARY
• New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer